Home » Beta amyloid-targeted therapeutic antibody

Beta amyloid-targeted therapeutic antibody

Modality

Biotherapeutics

Therapeutic area

Neuroscience

Advantages

A novel approach to specifically target Aβ N-terminal oligomers

Background info

TAPAS specifically recognises the truncated toxic forms pyroglutamate (AβpE3) and Aβ4-42, but not Aβ1-42 showed efficacy in vivo in different models of Alzheimer’s disease.

Indication

Alzheimer’s Disease

Intellectual property

Pending patent applications: WO20070225; Granted patents: EP2847217 B1; EP3269736 B1; US9617332 BB; HK11207869 B